JPRN-jRCT1080222405未知Unknown
ADCETRIS IV Infusion - Special drug use surveillance (all-case surveillance) Relapsed or refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphoma
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 140 人开始时间: 2014年2月24日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All patients treated with ADCETRIS IV Infusion
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Relapsed or refractory CD30-positive peripheral T cell lymphoma or Pediatric Hodgkin LymphomaPeripheral T cell lymphoma and Pediatric Hodgkin lymphomaJPRN-jRCT1080224999Takeda Pharmaceutical Company Limited95
已完成
不适用
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Untreated CD30-Positive Hodgkin's LymphomaJPRN-jRCT1080224121Takeda Pharmaceutical Company Limited113
招募中
不适用
A Survey of Brentuximab Vedotin in Pediatric Participants with Hodgkin LymphomaHodgkin LymphomaJPRN-jRCT2031220244Contact for Clinical Trial Information8
未知
Unknown
iovel Combination Tablets special drug use surveillance Long-term use in patients with type 2 diabetes mellitusJPRN-jRCT1080222253TAKEDA PHARMACEUTICAL COMPANY LTD.3,000
招募中
不适用
Special Drug Use Surveillance of Alecensa Capsules in Pediatric Patients- Recurrent or refractory ALK fusion gene-positive anaplastic large cell lymphomaRecurrent or refractory ALK fusion gene-positive anaplastic large cell lymphomaJPRN-UMIN000039803Chugai Pharmaceutical Co. Ltd.10